Results
To investigate the potential posttranscriptional control of ATR and ATM expression by SLFN11, we generated stable polyclonal derivatives from the pancreatic cancer cell line COLO 357/FG (hereafter referred to as FG cells) 13 and human embryonic kidney cells 293 (HEK 293) cells (hereafter referred to as 293 cells) using two independent lentivirus-based short hairpin RNA (shRNA) constructs against SLFN11 to permanently silence SLFN11 expression. Crucially, silencing SLFN11 expression conferred significant resistance of both FG and 293 cells to the topoisomerase I inhibitor camptothecin (CPT) ( Fig. 1a,d) , as well as other DDAs, including the topoisomerase II inhibitor mitoxantrone, the nucleoside analog gemcitabine and the DNA-alkylating and cross-linking agent chlorambucil ( Fig. 1g-i ). Further, microscopic imaging of live cell cultures confirmed that CPT treatment induced cell death in SLFN11-expressing cells but not in SLFN11-deficient cells (Fig. 1j ).
To determine whether SLFN11 affects translation of ATR and ATM in response to DNA damage, we first analyzed the expression levels of both ATR and ATM after CPT treatment. Indeed, expression of both proteins was significantly downregulated after 24 or 48 h of CPT exposure in FG and 293 cells, but were barely affected in their SLFN11-lacking matched counterparts ( Fig. 1b,e ). In contrast, both ATR and ATM messenger RNA (mRNA) levels stayed constant or were upregulated on CPT treatment (Fig. 1c,f) .
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ATM expression failed to do so (Fig. 2b,d) . The inherently SLFN11deficient pancreatic tumor cell line, MIA PaCa-2, was also sensitized to CPT treatment by siRNA-mediated suppression of ATR expression, corroborating these observations ( Fig. 2e-g) . Inhibition of ATR kinase activity by the small-molecule ATR inhibitor VE-822 also sensitized SLFN11-deficient cells to CPT treatment in a dosedependent manner ( Fig. 2h-k) . Our data also suggest that expression of SLFN11 did not affect the early DNA damage response signaling, as reflected by phosphorylation of checkpoint kinase 1 (CHK1) at serine 317 by ATR (Fig. 2i, lanes 1, 2, 6, 7) .
We performed 35 CPT treatment in both 293 and FG cells (Fig. 3a , lane 4) compared to their SLFN11-deficient counterparts (Fig. 3a, lane 10) . However, the stability of ATR protein did not appear to be affected by CPT or SLFN11, as evidenced by the relatively stable levels of newly synthesized 35 S-labeled ATR protein in the chase phase of the experiment ( Fig. 3a, protein synthesis, but not that of GAPDH, was observed as early as 3 h after CPT administration uniquely in SLFN11-expressing cells (Fig. 3b ). After 6 h of CPT treatment, slight inhibition of GAPDH translation was observed, while the inhibition of ATR protein synthesis consistently escalated ( Fig. 3b ). Moreover, polysome profiling experiments also showed that 6 h after CPT treatment was initiated, the ATR polysome profile changed much more substantially in SLFN11-expressing FG cells than in SLFN11-deficient FG cells. Importantly, only minor changes were observed in the GAPDH polysome profile on CPT treatment, regardless of the presence of SLFN11 ( Fig. 3c ). Altogether, these results demonstrate that on CPT treatment, a prominent inhibition of ATR protein synthesis occurs quickly following DNA damage.
To facilitate our further investigation of the molecular mechanism of SLFN11 function, we established SLFN11-deficient FG and 293 cell lines using CRISPR-Cas9 technology. Complete abrogation of SLFN11 expression via CRISPR-Cas9 yielded an even more profound phenotype of DDA resistance in both FG and 293 cells ( Fig. 4a-d ) without substantial effects on cell proliferation in the absence of DDAs (Fig. 4e) . A significant increase of caspase 3/7 activity in the presence of SLFN11 on CPT treatment ( Fig. 4f ), as well as shrinkage of cells and generation of apoptotic bodies ( Fig. 4g ), further suggest SLFN11 expression sensitizes cells to apoptosis on CPT treatment.
Our prior report of codon usage-dependent, selective translational inhibition of HIV-1 proteins provided initial evidence that SLFN11 affects cellular transfer RNA (tRNA) levels, particularly in infected cells 1 . We further investigated whether SLFN11 would potentially alter tRNA levels during the DNA damage response. The 70-87-nucleotide-long tRNAs can be divided into two groups based on the structure and size of their variable loops: tRNAs with a short variable loop of 4 or 5 nucleotides are classified as type I, whereas those harboring a long variable stem, totaling 13-19 bases, are referred to as type II tRNAs. In human cells, the longer type II tRNAs comprise all leucine tRNAs including Leu-AAG, Leu-CAA, Leu-CAG, Leu-TAA and Leu-TAG, and all serine tRNAs including Ser-AGA, Ser-CGA, Ser-GCT and Ser-TGA 14, 15 .
Unexpectedly, analysis of total tRNA abundance revealed that as early as 3 h after CPT treatment was initiated, the levels of type II tRNAs in FG cells already began to decline in a SLFN11-dependent manner (Fig. 5a,b ). After 12 h of CPT treatment, only ~50% of type II tRNAs were still present in SLFN11-expressing FG and 293 cells, whereas no such change was observed in their SLFN11-deficient counterparts. Strikingly, expression levels of type I tRNAs appeared unaffected in response to the DDA regardless of SLFN11 expression ( Fig. 5a-d ). Similar downregulation of type II tRNAs was also observed on mitoxantrone, gemcitabine or chlorambucil treatment in SLFN11-expressing FG cells ( Fig. 5e ,f). We additionally performed protein domain function analysis by expressing either the full-length, truncated N-terminal half (amino acid residues 1-579) or C-terminal half (amino acid residues 523-901) of SLFN11 in HEK 293T cells, which is distinguished from its parental cell line HEK 293 in that it lacks endogenous SLFN expression 1 . The result clearly indicated that the N-terminal half of SLFN11 contains the effector domain that suppresses type II tRNA levels ( Fig. 5g-i) .
Fig. 4 | cRISPR-cas9 mediated SLFN11 gene knockout confers significant resistance to cPt-induced apoptosis on cells without affecting cell
To identify the individual tRNAs that are downregulated on CPT treatment in the presence of SLFN11, we performed quantitative reverse transcription PCR-based microarray analysis on all nuclear-encoded tRNAs. The tRNAs were first demethylated using Escherichia coli alpha-ketoglutarate-dependent dioxygenase (AlkB) to allow efficient reverse transcription of tRNAs, following a protocol that we optimized based on two recent reports 16, 17 . The quantitative PCR (qPCR)-based microarray analysis demonstrated that all leucine tRNAs, as well as Ser-AGA, Ser-TGA and Ser-GGA tRNAs, were significantly downregulated after 12 h of CPT treatment in SLFN11-expressing FG cells ( Fig. 6a and Supplementary Dataset 2). Intriguingly, the only type I tRNA also affected was the initiator methionine tRNA Ini-CAT, whose complementary AUG codon represents the classical translation initiation site for most mRNAs 18, 19 . However, most important for our investigation was the finding that not a single tRNA, regardless of its type, was subdued in response to CPT in the absence of SLFN11 ( Fig. 6b and Supplementary Dataset 3).
Since the qPCR-based microarray evaluation is a novel, as yet unpublished method of tRNA quantification, we confirmed our findings by northern blot analyses. These assays revealed once again that downregulation of tRNAs Leu-TAA, Leu-CAA, Leu-CAG, Ser-AGA and Ini-CAT began as early as 3 h after CPT administration, followed by a decrease in Leu-TAG, Leu-AAG, Ser-CGA, Ser-GCT and Ser-TGA tRNAs 3 h later ( Fig. 6c ). Once more, attenuation of these tRNAs was evident only in cells expressing SLFN11 ( Fig. 6c ).
To further evaluate whether the specific type II tRNA suppression during the DNA damage response was the direct result of SLFN11 activation, we transiently expressed SLFN11 in SLFN11deficient HEK 293T cells. As shown in Fig. 6d , exogenous expression of SLFN11 alone was sufficient to reduce the levels of all type II serine and leucine tRNAs as well as tRNA Ini-CAT, whereas the type I tRNAs Thr-TGT and Val-TAC remained unchanged. Extended exposure of the tRNA northern blots visualized a fragment of corresponding type II tRNAs in CPT-treated, SLFN11-expressing FG cells, suggesting the SLFN11-mediated reduction of type II tRNAs on CPT treatment is probably the result of direct cleavage of tRNAs (Fig. 6e) . The direct cleavage model is also supported by the rapid decline of type II tRNAs immediately after CPT treatment started.
Our data thus far clearly illustrated that all leucine and serine tRNAs are targets of SLFN11. Therefore, we further investigated a possible selective impact of SLFN11 on the translation of genes adopting corresponding codons. To address this point, we designed a series of eGFP-encoding vectors in which each individual construct all leucine or serine residues were encoded by a single codon, with the original EGFP construct as the control. Each construct was then tested by transfection into SLFN11-deficient HEK293T cells, either with or without co-transfection of SLFN11-encoding vector. As demonstrated previously 1 , expression of the original EGFP protein was refractory to suppression by SLFN11 (Fig. 6f, lanes 1 and  2, both upper and lower panels) . Remarkably, SLFN11 completely abolished expression of enhanced green fluorescent protein (eGFP) eGFP_Leu(TTA), and to a lesser extent of eGFP_Leu(CTT); eGFP protein derived from all other constructs exhibited marginal or no alteration on account of the presence of SLFN11 (Fig. 6f ). Most importantly, the observed inhibition of specific eGFP expression occurred at the translational level, since SLFN11 did not significantly affect the level of eGFP mRNA regardless of the deriving construct ( Fig. 6g ).
We showed that moderate downregulation of tRNA-Leu-TAA by SLFN11 could inhibit the protein expression of genes with a high frequency of codon TTA (Leu) usage, such as ATR. Since siRNA-mediated knockdown of ATR expression sensitized the SLFN11-deficient cells to DDA, we wondered whether knockdown of tRNA-Leu-TAA would downregulate ATR protein expression and thus sensitize SLFN11-deficient cells to DDA also. Due to the heavy modification and extensive secondary structures of tRNAs, efficient knockdown of specific tRNAs via either siRNAs or shRNAs presents a substantial technical challenge. Therefore, we used a novel antisense oligonucleotide technique called gapmer 20, 21 to design specific gapmers targeting all four tRNA-Leu-TAA isodecoders. Gratifyingly, anti-tRNA-Leu-TAA gapmers downregulated the level of tRNA-Leu-TAA in both FG and FG-SLFN11KO cells, leading to profound inhibition of ATR protein expression ( Fig. 7a ). Interestingly, although anti-tRNA-Leu-TAA gapmer transfection alone triggered strong caspase 3/7 activation (Fig. 7b) , much more substantial cell death was observed only when the anti-tRNA-Leu-TAA gapmer transfected FG-SLFN11KO cells were treated by CPT sequentially, as evidenced by the MTS assay (3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) and microscopic imaging of live cell cultures (Fig. 7c,d) . The knockdown of tRNA-Leu-TAA by the corresponding gapmer was quite specific; it had only a minor effect on tRNA-Ser-CGA, which was partially targeted by the anti-tRNA-Leu-TAA gapmer (11 nt out of total 16 nt of gapmer Leu-TAA align with most Ser-CGA tRNA isodecoders). Similar results were obtained in intrinsically SLFN11-deficient MIA PaCa-2 cells ( Fig. 8a-d ).
Discussion
DDAs are the earliest and most widely used therapeutics for cancer treatment, accounting for almost one third of all chemotherapeutic drugs. However, many tumors are resistant to therapies based on DNA-damaging approaches. Even tumors that are initially responsive to the regimen routinely acquire resistance over the course of the treatment (reviewed in Cheung-Ong et al. 22 ). Two large-scale transcriptome profiling approaches revealed a clear requirement of SLFN11 in cancer cells for DDAs to trigger cell death 2, 3 . Most recently, a study showed that, in recurring small cell lung cancer, silencing of SLFN11 expression mediated by histone H3K27me3 modification at the SLFN11 gene locus was responsible for the tumor's acquired chemoresistance. Inhibition of histone-lysine N-methyltransferase EZH2 restored SLFN11 expression and resensitized the tumor cells to chemotherapy 23 . We found that early DNA damage response signals, such as the phosphorylation of CHK1, are not affected by SLFN11 expression; this is consistent with other reports that SLFN11 does not change early DNA damage responses but inhibits checkpoint maintenance and homologous recombination repair at the later stages. It was suggested that SLFN11 is promptly recruited to the sites of DNA damage via replication factor A protein 1 (RPA1) 24 , which could be a step in the as yet unknown activation mechanism of SLFN11. A recent independent study also reported that, on CPT treatment, SLFN11 is promptly recruited to chromatin at stressed replication foci via RPA1, but does not affect the early DNA damage response signaling event, such as phosphorylation of CHK1, or the loading of CDC45 and proliferating cell nuclear antigen 25 .
In this article, we describe a novel molecular mechanism by which SLFN11 sensitizes cells to apoptosis upon DNA damage. The SLFN11-dependent downregulation of type II tRNAs, most importantly tRNA-Leu-TAA, predisposes genes that are essential for the DNA damage response and repair, such as ATR or ATM, to translational inhibition as they use the corresponding codon TTA (Leu). At the onset of this study, we noted that synthesis of proteins encoded by genes with a low CAI resembling that of HIV were drastically more repressed by SLFN11 than the translation of genes with high CAI. The overall TTA (Leu) codon usage frequency is only about 8% for the human genome coding sequences, and 2% for the 24 most highly expressed human cellular proteins (Supplementary Table 4 ). In striking contrast, genes involved in HDR, NHEJ and MMR display much higher average TTA (Leu) codon usage (18, 15 and 13%, respectively), even when compared to genes affiliated with NER and BER (9 and 6%, respectively) ( Supplementary Tables  5 and 6 ). Indeed, out of the 352 leucines in ATR, 73 use the codon TTA (21%), and of 389 leucine residues in ATM, 91 are encoded by TTA (23%). In striking contrast, only a single TTA codon is found among the 19 leucine residues of GAPDH (5%). Our previous work demonstrated that the distinct codon bias facilitates preferential translational inhibition of HIV proteins by SLFN11. We now show that select mammalian genes, such as those associated with DNA damage response signaling (for example, ATR or ATM), harbor a similar codon usage distinction as HIV. Our more detailed analysis reveals that the frequency of TTA (Leu) codon usage is the apparent common denominator that subjects the encoded proteins to translational suppression by SLFN11 ( Supplementary Table 4 ). An outstanding question to be addressed in future is why only SLFN11-mediated degradation of tRNA-Leu-TAA affects the translation efficiency of mRNAs harboring the corresponding codon, whereas the cleavage of other leucine or serine tRNAs appears to be of lesser consequence. One possible explanation is the apparently lower abundance of tRNA-Leu-TAA (for codon TTA) that we have noted in our qPCR and northern blot analyses. Although neither technique permits a highly accurate quantitative assessment, they support a reasonable estimation of relative tRNA abundance. For instance, the qPCR cycle threshold (Ct) value for tRNA-Leu-CAG (for codon CTG) was about four cycles lower than the Ct value of tRNA-Leu-TAA (for codon TTA), suggesting the abundance of tRNA-Leu-CAG is roughly 16-fold higher than that of tRNA-Leu-TAA. A similar observation was reflected by the relative signal intensity in our northern blot analysis. Thus, for gene products requiring tRNA-Leu-TAA to support their translation, the availability of this tRNA may readily become the rate-limiting factor, and a consequent downregulation of tRNA-Leu-TAA may cause the ribosome to stall and/or detach at the corresponding TTA codons. This effect is expected to be amplified with the increased frequency of the TTA codon and with the length of the mRNA, with the end result that the longer the mRNA and higher the frequency of TTA codon usage for leucine residues increases the probability that premature translation termination will occur. In contrast, the translation rates for proteins that rely on more abundant, synonymous tRNAs will not be significantly affected by the reduced but nevertheless sufficient supply of required tRNAs.
Our present data show that the N-terminal half (amino acid residues 1-579) of human SLFN11 comprises the functional domain responsible for the degradation of type II tRNAs. It was reported that a leporine SLFN14 N-terminal fragment in rabbit reticulocyte lysate harbors endoribonuclease activity 26 . Furthermore, the crystallographic structure of the murine SLFN13 N-terminal domain (amino acid residues 14-353) was recently determined and shown to possess intrinsic tRNA and ribosomal RNA (rRNA)-targeting endoribonuclease activity in vitro 27 . In concert with our own studies, these findings firmly establish SLFN family members as a novel class of tRNA-specific endoribonucleases with the enzymatic activity residing in an N-terminal protein domain with an apparent specificity for type II tRNAs.
Mu et al. 24 reported that an SLFN11 deletion mutant lacking the extreme C-terminal sequence (amino acid residues 741-901) could not bind to RPA1 and was not recruited to DNA damage sites. This C-terminal deletion mutant also failed to resensitize SLFN11deficient cells to CPT. In contrast, we found that further deletion variants that retain only the N-terminal half of SLFN11 (amino acid residues 1-579) can degrade type II tRNAs, and, as we have previously shown, attenuate the translation of HIV proteins. One possible explanation for these findings is that the C-terminal half of SLFN11 acts as a regulatory domain with auto-inhibitory properties that are relieved by posttranslational modifications, which may occur at the sites of DNA damage. A short truncation as in Mu et al. 24 could possibly remove the site required for activation, but still retain enough of the C-terminal domain to inhibit such truncated SLFN11. However, the more extensive deletion that we employed may fully remove such inhibitory elements, and thus result in an active, albeit unregulated, SLFN11 fragment harboring a newly discovered tRNAse activity. In addition to the potential activation mechanisms of SLFN11, the subcellular location where it exerts its tRNA-degrading effects also requires further investigation. Although mature tRNAs generally function outside the nucleus, they move between the cytoplasm and the nucleus dynamically 28 , and thus may be susceptible to cleavage by SLFN11 regardless of their subcellular localization.
Although the cleavage of type II tRNAs by SLFN11, and consequent ATR suppression, are undoubtedly crucial components of DDA-induced cell death, our observations do not preclude the possibility that additional aspects of the DNA damage response are affected by SLFN11. Our studies do not rule out the possibility that induction of chromatin opening across replication initiation sites and blocking of fork progression by SLFN11 on CPT treatment may be an additional mechanism of SLFN11 function. However, as we show in this study, tRNA-Leu-TAA degradation with specifically targeted gapmers is sufficient to restore DNA damage-induced apoptosis via CPT in SLFN11-deficient cells, suggesting that this step is a crucial element of SLFN11 function.
In summary, our findings not only provide new insights into the molecular mechanism underlying SLFN11 function, but reveal that modulation of distinct tRNAs facilitates the specific targeting of proteins that rely on those tRNAs for their translation. The technical difficulty of manipulating specific tRNA expression has been a substantial obstacle to elucidating the role of tRNA levels and their contribution to the regulation of gene expression. In this article, we demonstrate for the first time that gapmer technology can be used to specifically attenuate the levels of individual tRNAs. The direct targeting of tRNA-Leu-TAA offers a new strategy to overcome tumor cell resistance to DDAs, and may hold unanticipated clinical potential.
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